Urinary n-acetyl-beta-d-glucosaminidase Excretion: An indicator of neuropathy in type 2 diabetes

Experimental and Clinical Endocrinology and Diabetes

Volumn 121, Issue 10, 2013, Pages 601-606

  Kopf, S ^a   Oikonomou, D ^a   Zdunek, D ^b   Von Eynatten, M ^c   Hess, G ^b   Nawroth, P P ^a   Bierhaus, A ^a   Humpert, P M ^a,d  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b ROCHE DIAGNOSTICS GMBH   (Germany)

^c BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^d Stoffwechselzentrum Rhein Pfalz   (Germany)

Author keywords

autonomic diabetic neuropathy; peripheral diabetic neuropathy; tubular damage; type 2 diabetes; urinary NAG

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ANTIDIABETIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHOLESTEROL; DIURETIC AGENT; GLUCOSE; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; N ACETYL BETA GLUCOSAMINIDASE; TRIACYLGLYCEROL;

ADULT; AGED; ALBUMINURIA; ARTICLE; AUTONOMIC NEUROPATHY; BODY MASS; CARDIOVASCULAR FUNCTION; CONTROL; CONTROLLED STUDY; DIABETIC NEUROPATHY; DISEASE ASSOCIATION; DISEASE MARKER; ENZYME ASSAY; ENZYMURIA; FEMALE; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; HEART; HUMAN; INDEPENDENT VARIABLE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SCREENING; URINALYSIS; URINARY EXCRETION;

ACETYLGLUCOSAMINIDASE; AGED; ALBUMINURIA; DIABETES MELLITUS, TYPE 2; DIABETIC NEUROPATHIES; FEMALE; HUMANS; MALE; MIDDLE AGED;

EID: 84889093597     PISSN: 09477349     EISSN: 14393646     Source Type: Journal    
DOI: 10.1055/s-0033-1355384     Document Type: Article

References (40)

1. Grundy S. M., Benjamin I. J., Burke G. L. et al. Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation: 1999; 100 1134 1146 (Pubitemid 29416243)
2. Almdal T., Scharling H., Jensen J. S. et al. The independent effect of type 2 diabetes mellitus on ischemic heart disease, stroke, and death: a population-based study of 13 000 men and women with 20 years of follow-up. Arch Intern Med: 2004; 164 1422 1426 (Pubitemid 38937853)
3. Haffner S. M., Lehto S., Ronnemaa T. et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med: 1998; 339 229 234 (Pubitemid 28350165)
4. Gaede P., Lund-Andersen H., Parving H. H. et al. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med: 2008; 358 580 591 (Pubitemid 351214285)
5. Nawroth P. P., Rudofsky G., Humpert P. Have we understood diabetes? New tasks for diagnosis and therapy. Exp Clin Endocrinol Diabetes: 2010; 118 1 3
6. Kotb N. A., Gaber R., Salah W. et al. Relations among glycemic control, circulating endothelial cells, nitric oxide, and flow mediated dilation in patients with type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes: 2012; 120 460 465
7. Dance N., Price R. G., Cattell W. R. et al. The excretion of N-acetyl-beta-glucosaminidase and beta-galactosidase by patients with renal disease. Clin Chim Acta: 1970; 27 87 92
8. Bosomworth M. P., Aparicio S. R., Hay A. W. Urine N-acetyl-beta-D- glucosaminidase - a marker of tubular damage? Nephrol Dial Transplant: 1999; 14 620 626 (Pubitemid 29105988)
9. Bazzi C., Petrini C., Rizza V. et al. Urinary N-acetyl-beta- glucosaminidase excretion is a marker of tubular cell dysfunction and a predictor of outcome in primary glomerulonephritis. Nephrol Dial Transplant: 2002; 17 1890 1896 (Pubitemid 35277084)
10. Nauta F. L., Boertien W. E., Bakker S. J. et al. Glomerular and tubular damage markers are elevated in patients with diabetes. Diabetes Care: 2011; 34 975 981
11. Gibey R., Dupond J. L., Henry J. C. Urinary N-acetyl-beta-D- glucosaminidase (NAG) isoenzyme profiles: a tool for evaluating nephrotoxicity of aminoglycosides and cephalosporins. Clin Chim Acta: 1984; 137 1 11 (Pubitemid 14179044)
12. Kalahasthi R. B., Rajmohan H., Rajan B. et al. Urinary N-acetyl-beta -D-glucosaminidase and its isoenzymes A & B in workers exposed to cadmium at cadmium plating. J Occup Med Toxicol: 2007; 2 5
13. Liangos O., Perianayagam M. C., Vaidya V. S. et al. Urinary N-acetyl-beta-(D)-glucosaminidase activity and kidney injury molecule-1 level are associated with adverse outcomes in acute renal failure. J Am Soc Nephrol: 2007; 18 904 912 (Pubitemid 46434507)
14. Huang R., Zhou Q., Veeraragoo P. et al. Notch2/Hes-1 pathway plays an important role in renal ischemia and reperfusion injury-associated inflammation and apoptosis and the gamma-secretase inhibitor DAPT has a nephroprotective effect. Ren Fail: 2011; 33 207 216
15. Araujo F. A., Rocha M. A., Ferreira M. A. et al. Implant-induced intraperitoneal inflammatory angiogenesis is attenuated by fluvastatin. Clin Exp Pharmacol Physiol: 2011; 38 262 268
16. Fu W. J., Xiong S. L., Fang Y. G. et al. Urinary tubular biomarkers in short-term type 2 diabetes mellitus patients: a cross-sectional study. Endocrine: 2011
17. Hong C. Y., Chia K. S., Ling S. L. Urinary protein excretion in Type 2 diabetes with complications. J Diabetes Complications: 2000; 14 259 265
18. Iqbal M. P., Sharif H. M., Mehboobali N. et al. N-acetyl-B-D- glucosaminidase and inflammatory response after cardiopulmonary bypass. J Coll Physicians Surg Pak: 2008; 18 74 77 (Pubitemid 351524073)
19. Brymora A., Flisinski M., Johnson R. J. et al. Low-fructose diet lowers blood pressure and inflammation in patients with chronic kidney disease. Nephrol Dial Transplant: 2011
20. Bierhaus A., Nawroth P. P. Multiple levels of regulation determine the role of the receptor for AGE (RAGE) as common soil in inflammation, immune responses and diabetes mellitus and its complications. Diabetologia: 2009; 52 2251 2263
21. Giacco F., Brownlee M. Oxidative stress and diabetic complications. Circ Res: 2010; 107 1058 1070
22. Mendler M., Schlotterer A., Morcos M. et al. Understanding diabetic polyneuropathy and longevity: what can we learn from the nematode Caenorhabditis elegans? Exp Clin Endocrinol Diabetes: 2012; 120 182 183
23. Roose S. P., Laghrissi-Thode F., Kennedy J. S. et al. Comparison of paroxetine and nortriptyline in depressed patients with ischemic heart disease. JAMA: 1998; 279 287 291 (Pubitemid 28071019)
24. von Eynatten M., Liu D., Hock C. et al. Urinary adiponectin excretion: a novel marker for vascular damage in type 2 diabetes. Diabetes: 2009; 58 2093 2099
25. Humpert P. M., Kopf S., Djuric Z. et al. Plasma sRAGE is independently associated with urinary albumin excretion in type 2 diabetes. Diabetes Care: 2006; 29 1111 1113 (Pubitemid 44115254)
26. Levey A. S., Stevens L. A., Schmid C. H. et al. A new equation to estimate glomerular filtration rate. Ann Intern Med: 2009; 150 604 612
27. von Eynatten M., Baumann M., Heemann U. et al. Urinary L-FABP and anaemia: distinct roles of urinary markers in type 2 diabetes. Eur J Clin Invest: 2010; 40 95 102
28. Ziegler D., Siekierka-Kleiser E., Meyer B. et al. Validation of a novel screening device (NeuroQuick) for quantitative assessment of small nerve fiber dysfunction as an early feature of diabetic polyneuropathy. Diabetes Care: 2005; 28 1169 1174 (Pubitemid 40616630)
29. Hilz M. J., Axelrod F. B., Hermann K. et al. Normative values of vibratory perception in 530 children, juveniles and adults aged 3-79 years. J Neurol Sci: 1998; 159 219 225 (Pubitemid 28384533)
30. Humpert P. M., Kopf S., Djuric Z. et al. Levels of three distinct p75 neurotrophin receptor forms found in human plasma are altered in type 2 diabetic patients. Diabetologia: 2007; 50 1517 1522 (Pubitemid 46879012)
31. Skrha J. Jr, Soupal J., Loni Ekali G. et al. Skin autofluorescence relates to soluble receptor for advanced glycation end-products and albuminuria in diabetes mellitus. J Diabetes Res: 2013; 2013 650694
32. Mulder D. J., Water T. V., Lutgers H. L. et al. Skin autofluorescence, a novel marker for glycemic and oxidative stress-derived advanced glycation endproducts: an overview of current clinical studies, evidence, and limitations. Diabetes Technol Ther: 2006; 8 523 535 (Pubitemid 44946877)
33. Agelink M. W., Malessa R., Baumann B. et al. Standardized tests of heart rate variability: normal ranges obtained from 309 healthy humans, and effects of age, gender, and heart rate. Clin Auton Res: 2001; 11 99 108 (Pubitemid 33027945)
34. Price R. G. The role of NAG (N-acetyl-beta-D-glucosaminidase) in the diagnosis of kidney disease including the monitoring of nephrotoxicity. Clin Nephrol: 1992; 38 01 S14 S19 (Pubitemid 23092540)
35. Takao T., Horino T., Kagawa T. et al. Possible involvement of intracellular angiotensin II receptor in high-glucose-induced damage in renal proximal tubular cells. J Nephrol: 2011; 24 218 224
36. Jin H. Y., Kang S. M., Liu W. J. et al. Comparison of peripheral nerve damages according to glucose control timing in experimental diabetes. Exp Clin Endocrinol Diabetes: 2012; 120 451 459
37. Samann A., Pofahl S., Lehmann T. et al. Diabetic nephropathy but not HbA1c is predictive for frequent complications of Charcot feet - long-term follow-up of 164 consecutive patients with 195 acute Charcot feet. Exp Clin Endocrinol Diabetes: 2012; 120 335 339
38. Lukic I. K., Humpert P. M., Nawroth P. P. et al. The RAGE pathway: activation and perpetuation in the pathogenesis of diabetic neuropathy. Ann N Y Acad Sci: 2008; 1126 76 80 (Pubitemid 351589321)
39. Sarafidis P. A., Bakris G. L. Microalbuminuria and chronic kidney disease as risk factors for cardiovascular disease. Nephrol Dial Transplant: 2006; 21 2366 2374 (Pubitemid 44644505)
40. Caramori M. L., Fioretto P., Mauer M. The need for early predictors of diabetic nephropathy risk: is albumin excretion rate sufficient? Diabetes: 2000; 49 1399 1408